Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bgc-20-1531 Free Base SCHEMBL2348089 | 1.00 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL3534655 | 0.90 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL3532327 | 0.89 | PTGER4 (0.81) | PTGER4 | |
| SCHEMBL3541275 | 0.86 | PTGER4 (0.80) | PTGER4 | |
| Bgc-20-1531 Free Base SCHEMBL29508262 | 0.84 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL4688621 | 0.84 | PTGER4 (1.00) | PTGER4 | |
| Bgc-20-1531 Free Base SCHEMBL30114901 | 0.84 | PTGER4 (1.00) | PTGER4 | |
| Bgc-20-1531 Free Base SCHEMBL2355810 | 0.84 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL4689376 | 0.83 | PTGER4 (0.87) | PTGER4 | |
| SCHEMBL14271689 | 0.81 | PTGER4 (0.71) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656246-A2 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-3134085-B1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | EISAI R&D MAN CO LTD (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-12240860-B2 | Heterobicyclic carboxylic acids and salts thereof | Foshan Ionova Biotherapeutics Co., Inc. (CN) | 2025-03-04 | — | — | US | disclosed |
| US-20240285640-A1 | COMBINATION THERAPY FOR TREATING PIK3CA-MUTATED CANCER | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| CN-111936502-B | Heterobicyclic carboxylic acids and salts thereof | 深圳市原力生命科学有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20230390303-A1 | CANCER TREATMENT BY COMBINATION OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-12-07 | — | — | US | disclosed |
| EP-4252774-A1 | COMBINATION THERAPY FOR TREATING PIK3CA-MUTATED CANCER | Adlai Nortye Biopharma Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| EP-4245301-A1 | CANCER TREATMENT BY COMBINED USE OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | ONO Pharmaceutical Co., Ltd. (JP) | 2023-09-20 | — | — | EP | disclosed |
| US-11707448-B2 | Combination therapies for the treatment of cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-07-25 | — | — | US | disclosed |
| CN-115697317-A | Use of EP4 receptor antagonists for the treatment of liver cancer, melanoma, lymphoma and leukemia | 株式会社AskAt | 2023-02-03 | — | — | CN | disclosed |
| WO-2022138793-A1 | COMBINATION BETWEEN EP2 RECEPTOR ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR AND/OR EP4 RECEPTOR ANTAGONIST | 小野薬品工業株式会社 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022138791-A1 | EP2 ANTAGONIST | 小野薬品工業株式会社 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022111714-A1 | COMBINATION THERAPY FOR TREATING PIK3CA-MUTATED CANCER | 杭州阿诺生物医药科技有限公司 | 2022-06-02 | — | — | WO | disclosed |
| WO-2022102731-A1 | CANCER TREATMENT BY COMBINED USE OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | 小野薬品工業株式会社 | 2022-05-19 | — | — | WO | disclosed |
| US-20220071959-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707448-B2 | Combination therapies for the treatment of cancer | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885 |
| US-20220071959-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885 |
| US-20240285640-A1 | COMBINATION THERAPY FOR TREATING PIK3CA-MUTATED CANCER | PIK3CA, PDPK1, PDCD1 | PTGER4 45/4885 |
| US-12240860-B2 | Heterobicyclic carboxylic acids and salts thereof | PTGER4, PTGER1, GPR4 | PTGER4 1/4885 |
| US-20230390303-A1 | CANCER TREATMENT BY COMBINATION OF EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITOR | CD274, PTGER4, PDCD1 | PTGER4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.